BioSpace News Archive

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that management will present at the following upcoming virtual investor conferences.

HotSpot Therapeutics, Inc. announced the presentation of additional pre-clinical data on the Company’s Casitas B-lineage lymphoma proto-oncogene program in a poster presentation at the American Association for Cancer Research Annual Meeting 2022.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing and global contract research services, announced that it plans to release its first quarter 2022, financial results on Wednesday, April 27, 2022.

IMV Inc. announced safety and preliminary efficacy data of the combination of the Company’s lead immunotherapy candidate, maveropepimut-S, with pembrolizumab from a Phase 2 basket study of patients with advanced, metastatic bladder cancer.

Mirum Pharmaceuticals, Inc. announced that on April 8, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,500 shares of common stock and 12,650 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

Modern medicine has evolved drastically over the years. From home remedies to targeted medicines, the healthcare sector has witnessed significant breakthroughs.

Nitric oxide has witnessed increased demand owing to its rise in use in the medical sector and during the Covid-19 pandemic.

Researchers from various universities and companies have been devising new ways to carry out nerve repair and regeneration. Innovative approaches and devices to speed up repair and regeneration processes of tissues and muscles have been launched.

Amniotic membrane (AM), also known as amnion, is a thin inner layer of the fetal placenta which surrounds the baby during pregnancy.

IO Biotech announced updated efficacy data and subgroup analyses from the MM1636 Phase 1/2 clinical trial evaluating IO102-IO103 as investigational agents in metastatic melanoma in an e-poster presentation at the American Association of Cancer Research conference, being held April 8-13, 2022 in New Orleans, Louisiana.